Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 2/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14800009 | 0.79 | ALDH1A1 (0.35) | — | |
| SCHEMBL13737906 | 0.71 | NOTUM (0.44) | — | |
| SCHEMBL142200 | 0.70 | — | — | |
| SCHEMBL8731401 | 0.70 | — | — | |
| SCHEMBL4723234 | 0.66 | TFPI2 (0.32) | — | |
| SCHEMBL5075298 | 0.65 | — | — | |
| SCHEMBL30793374 | 0.65 | — | — | |
| SCHEMBL18209849 | 0.64 | — | — | |
| SCHEMBL20658834 | 0.64 | — | — | |
| SCHEMBL28311023 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250185656-A1 | PIPERIDINONE DERIVATIVE OR SALT THEREOF, HARMFUL ORGANISM CONTROL AGENT CONTAINING SAID COMPOUND, AND METHOD FOR USING SAME | ADEKA CORPORATION (JP) | 2025-06-12 | — | — | US | disclosed |
| CN-116917293-A | Plasma kallikrein inhibitors | 默沙东有限责任公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-109311889-B | Activin receptor-like kinase inhibitors | 缆图药品公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-109415387-B | Arginase inhibitors and therapeutic uses thereof | 昂科艾伦迪治疗法公司 | 2021-08-27 | — | — | CN | disclosed |
| WO-2020117942-A1 | CHOLINE METABOLISM INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-06-11 | — | — | WO | disclosed |
| CN-105246890-A | Pyrrolo[2, 3-b]pyridine cdk9 kinase inhibitors | ABBVIE INC | 2016-01-13 | — | — | CN | disclosed |
| WO-2012160464-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-11-29 | — | — | WO | disclosed |
| EP-2279737-B1 | Heterocyclic compounds that are active as beta lactamase inhibitors | NOVEXEL (FR) | 2012-10-31 | — | — | EP | disclosed |
| EP-2279737-A1 | Heterocyclic compounds that are active as beta lactamase inhibitors | NOVEXEL (FR) | 2011-02-02 | — | — | EP | disclosed |
| EP-1480644-B1 | NOVEL HETEROCYCLIC COMPOUNDS WHICH ARE ACTIVE AS INHIBITORS OF BETA+LACTAMASES | NOVEXEL (FR) | 2010-10-13 | — | — | EP | disclosed |
| EP-1307457-B1 | AZABICYCLIC COMPOUNDS, PREPARATION THEREOF AND USE AS MEDICINES, IN PARTICULAR AS ANTIBACTERIAL AGENTS | AVENTIS PHARMA SA (FR) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250185656-A1 | PIPERIDINONE DERIVATIVE OR SALT THEREOF, HARMFUL ORGANISM CONTROL AGENT CONTAINING SAID COMPOUND, AND METHOD FOR USING SAME | EGLN1, STIP1, OSR1 | PSEN1 2579/4885PSEN2 3702/4885APH1B 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.